Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 9, 2012, Pages 765-773

  Sun, Chun ^a   Chen, Pei ^a   Chen, Qiaopei ^b   Sun, Lu ^a   Kang, Xiaonan ^a   Qin, Xue ^b   Liu, Yinkun ^a  

^a FUDAN UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

glycan biomarker; paraoxonase 1; serum glycoproteome; tandem lectin affinity chromatography

Indexed keywords

ARYLDIALKYLPHOSPHATASE; FUCOSE; GLYCOPROTEIN; N ACETYLNEURAMINIC ACID; TUMOR MARKER;

ADULT; ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYMOLOGY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ADULT; ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CHROMATOGRAPHY, LIQUID; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; FEMALE; FUCOSE; GLYCOPROTEINS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; ROC CURVE; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

ALEURIA AURANTIA; TRITICUM AESTIVUM;

EID: 84865600388     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms055     Document Type: Article

References (38)

1. Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA and Attino V, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002, 97: 397-405. (Pubitemid 34160767)
2. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D and Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alphafetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006, 101: 513-523. (Pubitemid 43340927)
3. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR and Hart GW, et al. Essentials of Glycobiology, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2009.
4. Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA and Stadheim LM, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007, 5: 394-402. (Pubitemid 46401522)
5. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H and Osaki Y, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutininreactive alpha-fetoprotein. J Gastroenterol Hepatol 2001, 16: 1378-1383. (Pubitemid 34107406)
6. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T and Taketa K, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993, 328: 1802-1806. (Pubitemid 23174710)
7. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR and Satomura S, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV related cirrhosis. Am J Gastroenterol 2007, 102: 2196-2205. (Pubitemid 47493844)
8. Wang SS, Lu RH, Lee FY, Chao Y, Huang YS, Chen CC and Lee SD. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996, 25: 166-171. (Pubitemid 26276628)
9. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A and Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006, 5: 1957-1967. (Pubitemid 44688203)
10. Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P, Di Bisceglie AM and Block T, et al. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One 2010, 5: e12419.
11. Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A and Marrero J, et al. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2011, 20: 1222-1229.
12. Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N and Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010, 56: 823-831.
13. Orntoft T and Vestergaard E. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999, 20: 362-371. (Pubitemid 29125024)
14. Kuno A, Ikehara Y, Tanaka Y, Angata T, Unno S, Sogabe M and Ozaki H, et al. Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. Clin Chem 2011, 57: 48-56.
15. Bunkenborg J, Pilch BJ, Podtelejnikov AV and Wiśniewski JR. Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 2004, 4: 454-456.
16. Chen R, Jiang X, Sun D, Han G, Wang F, Ye M and Wang L, et al. Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res 2009, 8: 651-661.
17. Liu T, Qian WJ, Gritsenko MA, Camp DG, II, Monroe ME, Moore RJ and Smith RD. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 2005, 4: 2070-2080. (Pubitemid 41814273)
18. Başkol M, Başkol G, Deniz K, Ozbakir O and Yücesoy M. A new marker for lipid peroxidation: serum paraoxonase activity in non-alcoholic steatohepatitis. Turk J Gastroenterol 2005, 16: 119-123. (Pubitemid 44869964)
19. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L and Joven J. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48: 261-268. (Pubitemid 34107262)
20. Chen P, Liu Y, Kang X, Sun L, Yang P and Tang Z. Identification of N-glycan of alpha-fetoprotein by lectin affinity microarray. J Cancer Res Clin Oncol 2008, 134: 851-860.
21. Dube DH and Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005, 4: 477-488. (Pubitemid 40861990)
22. Zhou SM, Cheng L, Guo SJ, Zhu H and Tao SC. Lectin microarray: a powerful tool for glycan related biomarker discovery. Comb Chem High Throughput Screen 2011, 14: 711-719.
23. Yang L, Guo S, Li Y, Zhou S and Tao S. Protein microarrays for systems biology. Acta Biochim Biophys Sin 2011, 43: 161-171.
24. Fry SA, Afrough B, Lomax-Browne HJ, Timms JF, Velentzis LS and Leathem AJ. Lectin microarray profiling of metastatic breast cancers. Glycobiology 2011, 21: 1060-1070.
25. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S and Evans AA, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006, 5: 308-315. (Pubitemid 43224256)
26. Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B and Long RE, et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 2009, 8: 595-602.
27. Kim KA, Lee EY, Kang JH, Lee HG, Kim JW, Kwon DH and Jang YJ, et al. Diagnostic accuracy of serum asialo-alpha1-acid glycoprotein concentration for the differential diagnosis of liver cirrhosis and hepatocellular carcinoma. Clin Chim Acta 2006, 369: 46-51. (Pubitemid 43796311)
28. Mehta A and Block TM. Fucosylated glycoproteins as markers of liver disease. Dis Markers 2008, 25: 259-265.
29. Ohkura T, Hada T, Higashino K, Ohue T, Kochibe N, Koide N and Yamashita K. Increase of fucosylated serum cholinesterase in relation to high risk groups for hepatocellular carcinomas. Cancer Res 1994, 54: 55-61. (Pubitemid 24042088)
30. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM and Block TM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009, 18: 1914-1921.
31. Zhang S, Shu H, Luo K, Kang X, Zhang Y, Lu H and Liu Y. N-linked glycan changes of serum haptoglobin b chain in liver disease patients. Mol Biosyst 2011, 7: 1621-1628.
32. Shu H, Zhang S, Kang X, Li S, Qin X, Sun C and Lu HJ, et al. Protein expression and fucosylated glycans of the serum haptoglobin b subunit in HBV-based liver diseases. Acta Biochim Biophys Sin 2011, 42: 528-534.
33. Lau KS and Dennis JW. N-Glycans in cancer progression. Glycobiology 2008, 18: 750-760.
34. Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, Kitada T and Honke K, et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res 2003, 63: 6282-6289. (Pubitemid 37255175)
35. Souady J, Hülsewig M, Distler U, Haier J, Denz A, Pilarsky C and Senninger N, et al. Differences in CD75s-and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinoma and non-tumoral liver tissues. Glycobiology 2010, 21: 584-594.
36. Wang H, Wang QY, Zhang Y, Shen ZH and Chen HL. Alpha1,3 Fucosyltransferase-VII modifies the susceptibility of apoptosis induced by ultraviolet and retinoic acid in human hepatocarcinoma cells. Glycoconj J 2007, 24: 207-220. (Pubitemid 46866642)
37. Lok AS and Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989, 9: 110-115. (Pubitemid 19046312)
38. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR and Reddy KR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137: 110-118.